Skip to Content
Merck
CN
All Photos(1)

Key Documents

View All Documentation

Safety Information

F8304

Sigma-Aldrich

Flavoxate hydrochloride

≥98% (HPLC), solid

Synonym(s):

3-Methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylic acid 2-(1-piperidinyl)ethyl ester hydrochloride, DW-61, Rec-7-0040

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C24H25NO4 · HCl
CAS Number:
3717-88-2
Molecular Weight:
427.92
EC Number:
223-066-4
MDL number:
MFCD00072099
UNSPSC Code:
12352200
PubChem Substance ID:
24724484
NACRES:
NA.77

Assay

≥98% (HPLC)

form

solid

color

white

solubility

H2O: ~6.6 mg/mL

originator

Johnson & Johnson

SMILES string

Cl[H].CC1=C(Oc2c(cccc2C1=O)C(=O)OCCN3CCCCC3)c4ccccc4

InChI

1S/C24H25NO4.ClH/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25;/h2,4-5,8-12H,3,6-7,13-16H2,1H3;1H

InChI key

XOEVKNFZUQEERE-UHFFFAOYSA-N

Gene Information

human ... PDE4A(5141) , PDE4B(5142) , PDE4C(5143) , PDE4D(5144) , PDE7A(5150) , PDE7B(27115) , PDE8A(5151) , PDE8B(8622)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Flavoxate, a flavone derivative and a tertiary-amine antimuscarinic possess antispasmodic properties. It is a strong smooth muscle relaxant that selectively acts on the pelvic region and is used in the symptomatic treatment of overactive bladder (OAB) and incontinence. Post-absorption in the gastrointestinal tract, flavoxate is localized in bladder, liver, and kidney tissues. It mediates the inhibition of phosphodiesterase (PDE) in the urinary bladder. Use of flavoxate aids pain relief in inflammatory disorders of the urinary tract.
L-type Ca2+ (Cav1.2) channel inhibitor

Features and Benefits

This compound is featured on the Calcium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H335

Hazard Classifications

Acute Tox. 4 Oral - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
016K4700

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Association between oxybutynin and neuropsychiatric adverse effects not confirmed in daily practice.
K L Movig et al.
Journal of the American Geriatrics Society, 49(2), 234-235 (2001-02-24)
Saori Nishijima et al.
The Journal of urology, 173(5), 1812-1816 (2005-04-12)
We examined the mechanism involved in the inhibition of bladder activity in rats by stimulating the rostral pontine reticular formation (RPRF) using carbachol, flavoxate and propiverine, and by analysis of amino acid levels in the lumbosacral cord. A total of
Bilateral acute angle closure glaucoma in a 50 year old female after oral administration of flavoxate.
Zakir Shaik Mohammed et al.
British journal of clinical pharmacology, 66(5), 726-727 (2008-08-30)
Rachna Sehgal et al.
Journal of tropical pediatrics, 53(4), 259-263 (2007-05-15)
A prospective study was done in pediatric out-patient department of a tertiary care hospital to evaluate the role of urodynamics in the management of primary enuresis in the 5-14-year-old children and to compare the effectiveness of multidimensional behavioral therapy with
Yanni F Yu et al.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 8(4), 495-505 (2005-08-11)
To investigate persistence and adherence of medication treatment in chronic overactive bladder/urinary incontinence (OAB/UI) patients, and to evaluate OAB/UI-related comorbidity events associated with persistence. Pharmaceutical outcomes research with a health-care provider perspective was conducted on a California Medicaid (Medi-Cal) chronic
View All Related Papers

Articles

Calcium Channels

We offers many products related to calcium channels for your research needs.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service